Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL

Marcel R.M. van den Brink, MD, PhD
Published Online: Wednesday, December 4, 2013
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin’s lymphoma (NHL).

Ibrutinib, a promising novel agent that blocks Bruton's tyrosine kinase activity, was analyzed in a phase I study in combination with R-CHOP in treatment-naive patients with CD20-positive B-cell non-Hodgkin’s lymphoma.

According to the abstract, the objective response rate (ORR) for the 15 evaluable patients was 100%, with a 73% complete response (CR) rate. Interim data specifically for the 22 patients with diffuse large B cell lymphoma (DLBCL) also demonstrated a 100% ORR, with a CR rate of 64%.

In the study, the combination of ibrutinib and R-CHOP had an acceptable safety profile. Many of the side effects associated with the treatment were similar to R-CHOP alone, the currently accepted standard of care for patients in this setting.

Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
OncoLogue: Breast Cancer Cases
Update From ASCO: Advances in Immunotherapy for Non–Small Cell Lung Cancer and Melanoma
More Reading
Publications
$auto_registration$